Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
(RTTNews) - On Friday, Outlook Therapeutics (OTLK), a biopharmaceutical company developing and commercializing LYTENAVA for retinal diseases, announced Greg DiPasquale as Chief Commercial Officer.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.